Kostas Biliouris
Stock Analyst at BMO Capital
(0.75)
# 3,707
Out of 4,784 analysts
54
Total ratings
23.91%
Success rate
-20.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $31.60 | +127.85% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $11.45 | +336.68% | 1 | Mar 12, 2025 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $50 | $7.59 | +558.76% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $3.44 | +626.74% | 2 | Mar 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $60 → $45 | $31.15 | +44.46% | 2 | Feb 20, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $8.07 | +519.58% | 6 | Jan 10, 2025 | |
| DTIL Precision BioSciences | Upgrades: Outperform | $34 | $4.70 | +623.40% | 3 | Jan 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $20 → $35 | $14.59 | +139.89% | 6 | Sep 16, 2024 | |
| MGX Metagenomi | Maintains: Outperform | $22 → $17 | $1.48 | +1,048.65% | 2 | Aug 15, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $63 → $40 | $3.63 | +1,001.93% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $35.06 | +156.70% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $234 | $268.46 | -12.84% | 4 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $200 | $70.41 | +184.05% | 4 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $17.44 | +588.07% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $22.21 | +156.64% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $35.11 | +5.38% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $71.44 | +39.98% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $1.99 | +854.77% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $62 | $5.22 | +1,087.74% | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $36.99 | +164.94% | 1 | Jun 17, 2022 |
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $31.60
Upside: +127.85%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $11.45
Upside: +336.68%
Rocket Pharmaceuticals
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $7.59
Upside: +558.76%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $3.44
Upside: +626.74%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Market Perform
Price Target: $60 → $45
Current: $31.15
Upside: +44.46%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $8.07
Upside: +519.58%
Precision BioSciences
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $4.70
Upside: +623.40%
Centessa Pharmaceuticals
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $14.59
Upside: +139.89%
Metagenomi
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.48
Upside: +1,048.65%
4D Molecular Therapeutics
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $3.63
Upside: +1,001.93%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $35.06
Upside: +156.70%
Jun 24, 2024
Maintains: Outperform
Price Target: $234
Current: $268.46
Upside: -12.84%
Jun 24, 2024
Maintains: Outperform
Price Target: $170 → $200
Current: $70.41
Upside: +184.05%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $17.44
Upside: +588.07%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $22.21
Upside: +156.64%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $35.11
Upside: +5.38%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $71.44
Upside: +39.98%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $1.99
Upside: +854.77%
Jul 18, 2022
Maintains: Outperform
Price Target: $48 → $62
Current: $5.22
Upside: +1,087.74%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $36.99
Upside: +164.94%